The receptor for epidermal growth factor (EGFR) also known as HER1 or ERBB1, is a transmembrane receptor tyrosine kinase of the ERBB family. This is a family of four receptors (ERBB1-4 or HER1-4) with EGFR the best characterized. EGFR is a prime target for cancer therapy across a broad variety of tumor types. Glioblastoma is the most common malignant brain tumor in adults, and among the most lethal of all cancers. Glioblastomas are divided into four subtypes: classical, proneural, mesenchymal and neural. EGFR amplification is enriched in the classical subtype. Amplification of the EGFR gene occurs in 57.4% of primary glioblastoma patients compared to 8% of secondary glioblastoma patients and is associated with high levels of EGFR protein. EGFR deletions in glioblastoma include EGFRvI (N-terminal deletion), vII (deletion of exons 14–15), vIII (deletion of exons 2–7), vIV (deletion of exons 25–27), vV (deletion of exons 25–28), among which vII and vIII are oncogenic.